Breaking News, Collaborations & Alliances

Eden Biodesign, Crucell in Vendor Network Pact

Watson Pharmaceuticals’ Eden Biodesign, Ltd., has entered a non-exclusive vendor network agreement with Crucell, under which Eden Biodesign becomes an authorized provider of process development and cGMP manufacturing services using Crucell’s P

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Watson Pharmaceuticals’ Eden Biodesign, Ltd., has entered a non-exclusive vendor network agreement with Crucell, under which Eden Biodesign becomes an authorized provider of process development and cGMP manufacturing services using Crucell’s PER.C6 cell line technology. Crucell’s human PER.C6 cell line is manufacturing system for high-yield, large-scale production of vaccines, recombinant proteins and gene therapy products. Eden Biodesign will also be able to offer its services to Crucell’s PER....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters